Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Marie Skłodowska-Curie Action · Running

ACHILLES Advancing in the CHallenge of Improving Lymphoma and LEukemia Survival

Coordinator
Fundacio Institut De Recerca Contra La Leucemia Josep Carreras, Spain
Runs
1 December 2025 to 30 November 2029
Status
Running
EU funding
€4.3m
Total cost
—
Partners
33 organisations in 12 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101227725

What the project is doing

In the project's own words, from its summary on CORDIS.

ACHILLES is a Doctoral Network (DN) program designed to train the next generation of leaders in hemato-oncology, with a focus on the development of novel therapeutic solutions for hematological malignancies. The network brings together 14 institutions from 10 EU countries and one associated state, along with partners from the biotechnology and drug discovery sectors, including two European policy leaders in hematology, the European Hematology Association (EHA) and the European School of Hematology (ESH).

Through this collaboration, ACHILLES will train 16 Doctoral Candidates (DCs) to develop essential skills in experimental hemato-oncology, including the design, development, and preclinical validation of innovative therapies. ACHILLES is structured around three key scientific objectives (SOs): (1) creating novel experimental models and analytical methods, (2) exploring the oncogenic mechanisms of hematologic malignancies, and (3) developing and validating new therapies, especially targeted treatments for leukemia and lymphoma.

The program will integrate cutting-edge technologies such as AI, multi-omics, and computational modeling to push the boundaries of current research and therapy development. These innovations will be applied to generate better diagnostic tools, predict treatment responses, and optimize therapeutic strategies. With a patient-centered approach, ACHILLES aims to foster both academic and industrial collaboration, bridging gaps between scientific research and clinical application.

This initiative aligns with the EU's Beating Cancer Plan, with a particular focus on improving survival rates and treatment accessibility, especially in Widening Countries. Through strong academic-industrial partnerships, ACHILLES will help create a sustainable impact on the field of hemato-oncology, advancing research, therapies, and ultimately the health outcomes of leukemia and lymphoma patients worldwide.

Topics

Who is involved

OrganisationCityCountryRole
Fundacio Institut De Recerca Contra La Leucemia Josep CarrerasBadalonaSpainCoordinator
Institute of Mathematics and Informatics at the Bulgarian Academy of ScienceSofiaBulgariaParticipant
Eidgenoessische Technische Hochschule ZuerichZuerichSwitzerlandAssociatedpartner
Eberhard Karls Universitaet TuebingenTuebingenGermanyParticipant
Leadership Sculptor GmbHBaden-BadenGermanyAssociatedpartner
Saso KocevarHeidelbergGermanyAssociatedpartner
Sonja NossWiesbadenGermanyAssociatedpartner
Ethniko Idryma ErevnonAthinaGreeceParticipant
Panepistimio Dytikis AttikisAigaleoGreeceAssociatedpartner
Cobiomic Bioscience SLCordobaSpainAssociatedpartner
Fundacio Centre De Regulacio GenomicaBarcelonaSpainAssociatedpartner
Fundacio Privada per a La Recerca I La Docencia Sant Joan De DeuEsplugues De LlobregatSpainAssociatedpartner
Fundació Internacional Josep CarrerasBarcelonaSpainAssociatedpartner
Institut De Investigacio En Ciencies De La Salut Germans Trias I PujolBadalona BarcelonaSpainAssociatedpartner
Onechain Immunotherapeutics S.l.BarcelonaSpainParticipant
Scienseed SLMadridSpainAssociatedpartner
Universidad Complutense De MadridMadridSpainParticipant
Universitat De BarcelonaBarcelonaSpainAssociatedpartner
European School of HaematologyParisFranceAssociatedpartner
Universite Paris CiteParisFranceParticipant
Universita' Degli Studi Di Milano-BicoccaMilanoItalyParticipant
European Hematology AssociationDen HaagNetherlandsAssociatedpartner
Stichting Amsterdam UmcAmsterdamNetherlandsParticipant
Stichting VuAmsterdamNetherlandsAssociatedpartner
I3s - Instituto De Investigacao E Inovacao Em Saude Da Universidade Do PortoPortoPortugalParticipant
Universidade Do PortoPortoPortugalAssociatedpartner
Universitatea De Medicina Si Farmacie Iuliu Hatieganu Cluj-NapocaCluj-NapocaRomaniaParticipant
Farmaceutski Fakultet Univerziteta U BeograduBelgradeSerbiaParticipant
Karolinska InstitutetStockholmSwedenParticipant
Lunds UniversitetLundSwedenAssociatedpartner
Lead Biologics International ABLundSwedenParticipant
Pixelgen Technologies ABStockholmSwedenAssociatedpartner
Sprint Bioscience ABHuddingeSwedenAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS